Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

8:25 MIN

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies

Jeffrey A. Allen, MD

University of Minnesota

12:50 MIN

CIDP
MMN

Review options for individualizing treatment and tools used to assess IgG performance

DOWNLOAD PDF

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

5:51 MIN

CIDP
GBS

Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.

DOWNLOAD PDF

NOW PLAYING

8:25

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING

25:18

Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING

12:50

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies

Review options for individualizing treatment and tools used to assess IgG performance

NOW PLAYING

5:51

IgG Levels and Wear Off Reflect Administration and Outcome

Our Experts on CIDP

VIEW ALL EXPERTS

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

CIDP
GBS

Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

Jeffrey A. Allen, MD

University of Minnesota